The FDA has approved Aqneursa (levacetylleucine) for ataxia in adult and pediatric patients with ataxia-telangiectasia weighing at least 15 kg.

There may be a dose-dependent association between eating more whole grains and the reduction of several major cardiovascular risk factors.

Many suspected poisonings among young children can be handled by a local poison control center despite frequent reliance on ED visits.

Evaluating combinations of modifiable and nonmodifiable risk factors improves risk stratification for late-onset Parkinson disease.

Long-term fumarate therapy for multiple sclerosis, compared with anti-CD20 therapy, is linked to a reduced risk for infection.

Improved cardiovascular health may help manage symptoms of overactive bladder based on a nonlinear association between each factor.

ADHD is associated with a significant increase in gastrointestinal symptoms compared with those that do not have ADHD.

The FDA approved Isembyld (apitegromab-mstn) for adults and pediatric patients aged 2 years and older with spinal muscular atrophy (SMA) receiving SMN2-targeted therapy.

Adults with chronic cough exhibited significant reductions in GMV across multiple brain regions when compared with a healthy control group.

Test your knowledge on recent migraine research, including pediatric adverse events and the magnitude of placebo responses.

A novel speech-based model successfully distinguishes between nonfluent, logopenic, and semantic variants of primary progressive aphasia.

The FDA granted Priority Review to satralizumab for MOGAD, a rare CNS demyelinating disease, backed by phase 3 METEOROID trial data showing a 68% risk reduction.